Head-To-Head Comparison: Phathom Pharmaceuticals (NASDAQ:PHAT) & Starpharma (OTCMKTS:SPHRY)

Starpharma (OTCMKTS:SPHRY) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Valuation & Earnings

This table compares Starpharma and Phathom Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Starpharma	$3.18 million	30.25	-$6.47 million	N/A	N/A
Phathom Pharmaceuticals	$147.19 million	8.77	-$334.33 million	($3.82)	-4.75

Starpharma has higher earnings, but lower revenue than Phathom Pharmaceuticals.

Analyst Ratings

This is a summary of current ratings for Starpharma and Phathom Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Starpharma	0	0	0	0	0.00
Phathom Pharmaceuticals	1	2	4	2	2.78

Phathom Pharmaceuticals has a consensus price target of $21.00, indicating a potential upside of 15.67%. Given Phathom Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Starpharma.

Institutional & Insider Ownership

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 23.0% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Starpharma has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.

Profitability

This table compares Starpharma and Phathom Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Starpharma	N/A	N/A	N/A
Phathom Pharmaceuticals	-186.53%	N/A	-79.41%

Summary

Phathom Pharmaceuticals beats Starpharma on 7 of the 12 factors compared between the two stocks.

About Starpharma

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.